undamentalytics Newsletter
Sign in

Clinuvel Pharmaceuticals Ltd cash flow statement

In fiscal 2026, Clinuvel Pharmaceuticals Ltd's operations generated $12.9m of cash; it spent $1.1m on capital projects, leaving free cash flow of $11.8m. It returned $1.7m in dividends.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Jun 20242025Jun 20252026Jun 2026
Cash from operations242713
Depreciation and amortisation010
Stock-based pay412
Capital spending401
Free cash flow202712
Free cash flow after stock pay162610
Dividends paid222
Share buybacks00—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ABCL vs CUVLCUVL vs CYTKCUVL vs RXRXCUVL vs NTLA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Clinuvel Pharmaceuticals Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Clinuvel Pharmaceuticals Ltd.